1 MAJOR ARTICLE

2 Community-based surveys for *Plasmodium falciparum pfhrp2* and *pfhrp3* gene deletions in

3 selected regions of mainland Tanzania

- 4 Catherine Bakari^{1,2}, Sophie Jones^{3,4}, Gireesh Subramaniam^{3,5}, Celine I. Mandara^{2,6}, Mercy G.
- 5 Chiduo², Susan Rumisha⁷ Frank Chacky⁸, Fabrizio Molteni⁸, Renata Mandike⁸, Sigsbert Mkude⁸,
- 6 Ritha Njau¹⁰, Camelia Herman^{3,9}, Douglas P. Nace³, Ally Mohamed⁷, Venkatachalam
- 7 Udhayakumar³, Caleb K. Kibet¹, Steven G. Nyanjom¹, Eric Rogier³, Deus S. Ishengoma^{7,11,12*}
- 8
- 9 ¹ Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya
- ¹⁰ ² National Institute for Medical Research, Tanga Research Centre, Tanga, Tanzania
- ³Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and
- 12 Prevention, Atlanta, GA, USA
- 13 ⁴Williams Consulting, Baltimore, Maryland, USA
- ⁵Oak Ridge Institute for Science and Education, Atlanta, Georgia, USA ⁶Kilimanjaro Christian
- 15 Medical University College, Moshi Tanzania
- 16 ⁶Kilimanjaro Christian Medical University College, Moshi Tanzania
- ¹⁷ ⁷National Institute for Medical Research, Headquarters, Dar es Salaam, Tanzania.
- 18 ⁸ National Malaria Control Program (NMCP), Dodoma, Tanzania
- ⁹ CDC Foundation (CDCF), Atlanta, GA, USA
- 20 ¹⁰World Health Organization (WHO) Country Office, Dar es Salaam, Tanzania
- 21 ¹¹ Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia

- 22 ¹²Harvard T. C Chan School of Public Health, Boston, MA, USA
- 23
- 24 **Running Title**: Lack of *pfhrp2* and *pfhrp3* gene deletions in Tanzania
- 25
- 26 WORD COUNT
- 27 Abstract: 199
- 28 Main Text: 4011
- 29

30	
31	Footnotes
32	
33	This work was supported by The Global Fund, CDC and DELGEME Project.
34	
35	The authors declare they have no competing interests. None of the material has been presented or
36	published previously.
37	
38	
39	
40	*Corresponding author: <u>deusishe@yahoo.com</u>
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	

56

57 ABSTRACT

Background: Despite recent reports of false negative results among histidine-rich protein 2 (HRP2)
based-malaria rapid diagnostic tests (mRDTs) caused by *pfhrp2/3* gene deletions in different
countries, there is paucity of data in Tanzania.

61 **Methods:** This study assessed the status of *pfhrp2/3* deletions in 7,543 blood samples using 62 laboratory multiplex antigen detection (*Plasmodium* lactate dehydrogenase - pLDH, aldolase, and 63 HRP2). Samples showing mRDT false negativity or aberrant relationship of HRP2 to pan-64 *Plasmodium* antigens were genotyped for *pfhrp2/3* genes.

65 **Results**: Of all samples, 2,417 (32.0%) were positive for any *Plasmodium* antigens while 5,126 66 (68.0%) were negative. About 99.8% (n=2,411) of antigen positive samples had HRP2, but 6 67 (0.2%) had only pLDH and/or pAldolase. Thirteen samples had atypical relationships between pan-68 *Plasmodium* antigens and HRP2, but were positive by PCR. An additional 16 samples with negative 69 HRP2 mRDTs but positive by microscopy were also chosen; all giving 35 samples genotyped for 70 pfhrp2/3. Of 35 samples, 4 (11.4%) failed to consistently amplify positive control genes (pfmsp1 71 and *pfmsp2*), and *pfhrp2* and *pfhrp3* genes were successfully amplified in 31 (88.6%) samples. 72 **Conclusions:** Lack of *pfhrp2* and/or *pfhrp3* genes deletions in *Plasmodium falciparum* parasites 73 supports continued use of HRP2-based mRDTs for routine malaria diagnosis in Tanzania.

74

75 Keywords

- 76 Tanzania; malaria; rapid diagnostic tests; histidine-rich protein 2/3; Lactate dehydrogenase,
 77 aldolase, *Plasmodium falciparum*
- 78
- 79
- 80

81

82

83 INTRODUCTION

84 Upon successful establishment of blood-stage infection by the *Plasmodium* parasites, various 85 parasite proteins are produced and released into the host blood. Some of these proteins (also 86 referred to as antigens) are targets for malaria rapid diagnostic tests (mRDTs). Three antigen targets currently in use include the Plasmodium lactate dehydrogenase (pLDH), Plasmodium aldolase 87 88 (pAldolase), and the *Plasmodium falciparum*-specific histidine rich protein 2 (HRP2)[1–3]. The use 89 of antigen-based mRDTs in many malaria endemic countries worldwide have profoundly improved 90 malaria case management and surveillance efforts and remains an essential diagnostic tool, 91 especially in Africa [4–7].

92 HRP2-based tests are species-specific since the antigen is only produced by *P. falciparum*, though 93 tests detecting pLDH and pAldolase have the potential to detect all human malarias [2,4,8]. HRP2 is 94 the most widely used antigen in mRDTs either alone or in combination with other antigens, due to 95 its abundance, specificity for *P. falciparum* infection, and high sensitivity and thermal stability [9]. 96 Antibodies raised against HRP2 can cross-react with the P. falciparum HRP3 antigen due to 97 similarities in amino acid sequences and repeating epitopes [10–12]. The genes encoding for these 98 two antigens are located on different chromosomes of the *P. falciparum* genome, with *pfhrp2* on 99 chromosome 8 while *pfhrp3* gene is on chromosome 13 [13,14]. Large number of genetic deletions 100 of pfhrp2 and/or pfhrp3 genes in natural populations of P. falciparum were first reported in parasite 101 populations in Peru and subsequently in many countries including Africa [15-22].

Sensitivity of HRP2-based mRDTs can be affected by transportation and storage conditions outside of manufacturer specifications, operator errors, low density infections, or a mutation or deletion of the *pfhrp2* and/or *pfhrp3* genes in the infecting parasite strain [15–23]. In addition, the diversity in parasite population and number of epitopes on HRP2 recognized by the diagnostic test antibodies may modify the sensitivity of the test when dealing with different *P. falciparum* populations [24– 28].

108 In Tanzania, mRDTs were introduced between 2009 and 2012 and are now widely used in both 109 private and public health facilities throughout the country. Before the introduction of mRDTs in 110 Tanzania, a study conducted between 2005 and 2010 (the African Quinine Artesunate Malaria 111 Treatment Trial) found no evidence of *pfhrp2/3* gene deletions [29]. However, *pfhrp2* gene 112 deletions have been reported in the neighbouring East African countries, including Kenya [21] and 113 Rwanda [27]. In addition, a study conducted in Tanzania which analysed samples collected in 2010 114 showed evidence of sporadic occurrence of pfhrp2/3 gene deletions in some areas [30]. Although 115 both the initial evidence (sample confirmed as microscopy positive for P. falciparum but negative 116 PfHRP2-detecting mRDTs) and confirmatory evidence (molecular approaches) [31] were used to 117 screen for pfhrp2/3 gene deletions, the sample size and the geographic regions covered were 118 limited. In this study, field diagnostic results and a multiplex antigen detection assay was used to 119 investigate potential pfhrp2/3 gene deletions in samples collected in 2017 from four regions of 120 Tanzania with persistently high malaria transmission after five years of introduction of mRDTs.

121

122 MATERIALS AND METHODS

123 Study sites

124 Samples and data were obtained from a cross-sectional survey conducted between July and 125 November 2017 in four regions of Tanzania (Geita, Kigoma, Mtwara and Ruvuma). These regions 126 were among those with persistently high malaria transmission as shown by the surveys conducted 127 from 2007 – 2017 [32–35]. The four Regions also had higher prevalence in the School Malaria 128 Parasitological Survey (SMPS) of 2014/2015 [36], and are among the 10 regions targeted by the 129 National Malaria Control Programme (NMCP) for reduction of malaria burden through the high 130 burden to high impact initiative (WHO and NMCP revised strategic plan). Two districts with high 131 prevalence in the SMPS of 2014/2015 were purposively selected from each region; Nyang'hwale 132 and Chato (Geita), Buhigwe and Uvinza (Kigoma), Mtwara DC and Nanyumbu (Mtwara) and 133 Nyasa and Tunduru (Ruvuma). Within each district, two villages were purposively selected for

134 sampling based on the malaria parasite positivity rates as reported from health facility reports, 135 making a total of 16 villages sampled all members of the selected households (HHs) were asked to 136 participate in the survey [37]. Blood samples were collected by finger prick, thin and thick films 137 were prepared, and all study participants were screened with malaria mRDT as per the manufacturer's instructions. CareStart Malaria HRP2/pLDH (Pf/PAN) COMBO (AccessBio,NJ, 138 139 USA) mRDTs were used in Geita and Kigoma regions, and Lundo village of Nyasa District 140 (Ruvuma region) while CareStart Malaria HRP2 (Pf) (AccessBio,NJ, USA) were used in the rest of 141 the villages in Ruvuma and Mtwara regions. The results were interpreted within the specified 142 reading time of the manufacturer's protocol. Dried blood spots on filter papers (DBS) were 143 collected on Whatman 3MM paper (GE Healthcare, PA, USA), dried for 2-4 hours, and individually 144 packaged in sealable plastic bags with desiccant for further laboratory analysis. Participants with 145 mRDT positive results were treated according to the national guidelines [38].

146

147 The main study and the laboratory analyses reported in this manuscript obtained ethical approval 148 from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical 149 Research (NIMR), and permission to conduct the study in the selected regions was sought from the 150 President's Office, Regional Administration and Local Government Authority and Regional, District 151 and village authorities. Informed consent/assent was sought before conducting the demographic 152 survey or including the participants into the study. The laboratory activities undertaken at CDC 153 were considered non-research by the CDC Human Subjects office for the purpose of providing 154 laboratory testing of these specimens and participation of CDC scientists for this collaboration.

155

156 Microscopy

157 Thick and thin blood films for parasite counting and species identification were prepared from the 158 finger prick blood and stained using 2.5–3% Giemsa for 45–60 minutes. The films were examined 159 by trained microscopists to detect parasite infection status and parasite density using thick films

while parasite species were assessed on thin films. Parasites were counted as asexual parasites per 200 White Blood Cells (WBCs) for asexual parasites or 500 WBCs for sexual stages. A blood film was declared negative if no *Plasmodium* parasites were detected after examining 200 high power fields for the thick film. Parasite density (parasites per μ L of blood) was calculated by multiplying the number of asexual parasites by 40 or sexual stages by 16 assuming one microliter of blood contained 8000 WBC.

166

167 Sample processing and Laboratory Multiplex Assay

168 DBS were shipped to the Malaria Laboratory, Centers for Disease Control and Prevention, Atlanta, 169 under ambient temperature. A 6mm punch of each sample was taken and eluted in blocking buffer 170 containing: PBS, 0.5% polyvinyl alcohol (Sigma, St. Louis, MO), 0.8% polyvinylpyrrolidine 171 (Sigma), 0.1% casein (ThermoFisher Scientific, Waltham, MA), 0.5% BSA (Sigma), 0.3% Tween-172 20, 0.05% sodium azide, and 0.01% E. coli extract to prevent non-specific binding. The elution step 173 diluted the samples to a 1:20x whole blood dilution, which was the dilution used for the assay. DBS 174 samples were screened by a bead-based multiplex antigen assay for the simultaneous detection of P. 175 falciparum HRP2 (HRP2), pan-Plasmodium aldolase (pAldolase), and pan-Plasmodium lactate 176 dehydrogenase (pLDH) by previously-described protocol [39]. Antibodies used to detect epitopes 177 on HRP2 would also bind to the same epitopes on the HRP3 antigen. Protocol details are outlined in 178 the Supplemental Data.

179

180 DNA Extraction, PET-PCR, *pfhrp2* and *pfhrp3* genotyping

For samples selected for further molecular characterization, genomic DNA was extracted from DBS using the QIAamp DNA Mini Kit (Hilden, Germany) using manufacturers protocol and screened for parasite DNA using the multiplex photo-induced electron transfer PCR (PET-PCR) assay as previously described [40–43]. PCR for *pfhrp2* and *pfhrp3* genotyping was performed as described previously [44,45]. Complete details for the molecular assays are outlined in Supplemental Data: (Supplemental Table1; Details of Primers and PCR reaction conditions to amplify *pfhrp2* and

pfhrp3 genes and Supplemental Table 2; Details of Primers and PCR reaction conditions to amplify *msp-1* and *msp-2* genes).

189

190

191 Data analysis

192 The database and the different data collection applications were created using the Open Data Kit 193 (ODK) software. Data cleaning, validation and quality control were undertaken as described by 194 Chiduo *et al* [37] .The data was later transferred to Microsoft Excel (Redmond, WA, USA) and 195 STATA software (Texas, USA) used for analysis which involved generating a summary of basic 196 features of the study population.

197 To determine if a sample's laboratory mean fluorescence intensity minus background signal (MFI-198 bg) was to be denoted as positive for a specific antigen, two methods were employed. First, a panel 199 of 24 known negative blood samples which had been eluted from Whatman 903 filter paper were 200 run by the multiplex antigen assay, the lognormal mean and standard deviation was derived from 201 this sample set. The mean +3sd was calculated to provide a MFI-bg threshold signal which was 202 used as a cutoff to define antigen positive samples. Second, a two-component finite mixture model 203 was used for the log-transformed antigen MFI-bg data from the study, and the mean +3sd of the first 204 component was used to define this cutoff. In order to reduce Type I errors, the more conservative of 205 these two methods was used to determine the MFI-bg signal where any sample values above this 206 would be considered a true positive for that particular antigen [46].

In comparing HRP2 antigen signal to either of the pan-*Plasmodium* markers, the typical relationship between these two antigens was defined as the standard correlation observed for the vast majority of the observations. Visual outliers to this standard correlation were identified as outliers with suspicion of aberrant HRP2 production by the *P. falciparum* parasite requiring further molecular investigation.

212

213 **RESULTS**

214 A total of 2,520 households with 7,313 individuals were sampled for the cross-sectional survey, 215 which was conducted in 16 villages (in 8 districts) from four regions of Tanzania (Geita, Kigoma, 216 Mtwara and Ruvuma) between July and November 2017 (Table 1). Apart from the 7,313 individuals 217 enrolled, an additional of 230 samples were taken from individuals who came to seek health 218 services, but were not among the 120 sampled households. Therefore, 7,543 blood samples were 219 available for this study, and 3.0% (230/7,543) of these were from individuals with incomplete data. 220 The remainder (97.0%, 7,313/7,543) had complete data with parasitological, clinical and 221 demographic information. The mean age in years was 22.3 (SD=21.0), and 43.4% of participants

- were male (Table 1).
- 223

For all persons enrolled in all study sites, 38.4% (2897/7543) were positive for any one of the three parasite detection assays: microscopy, mRDT, or bead-based multiplex assay. The results showed 15.8% (1,158/7,313) of the persons were positive for *P. falciparum* infection by microscopy, 33.3% (2,437/7,313) were positive by HRP2 mRDT, and 32.0% (2,417/7,543) were positive for any one of the *Plasmodium* antigens tested by the bead-based multiplex assay. Concordance among these three malaria tests is shown in Supplemental Figure 1. For those positive by microscopy, the geometric mean parasite density was 575 asexual parasites/µL of blood.

231

232 A flow diagram for sample selection for further molecular testing to detect the presence (and 233 potential prevalence) of *pfhrp2* and *pfhrp3* deletions in this study population is shown in Figure 2. 234 In selecting specimens warranting molecular assays for *pfhrp2* and *pfhrp3* genotyping, two types of 235 information were considered: discordance between field microscopy and mRDT results for an 236 individual, and relationship between the pan-Plasmodium antigens and the HRP2 antigen for an 237 individual's blood sample. From the field tests (microscopy and mRDT), 95 persons were found to 238 be microscopy positive but mRDT negative (1.3% of the 7313 persons who had data for both tests). 239 Of these 95 persons, 94 had a DBS available for multiplex antigen detection, and 54.3% (51/94) of

these were found to be HRP2 antigen positive by the laboratory test with a typical relationship to the other pan-*Plasmodium* antigens (as illustrated in Figure 3). Additionally, 28.7% (27/94) of these samples were negative for *P. falciparum* DNA and could not undergo genotyping. The remaining 16 samples (17.0% of the 94 selected by microscopy/mRDT discordance) were all *P. falciparum* DNA positive, but had no antigens detected (n=7) or an atypical relationship between the pan-*Plasmodium* markers and HRP2 (n=9). Based on these test results, these 16 were selected as warranting *pfhrp2* and *pfhrp3* genotyping.

247

248 Since all DBS were screened by the multiplex antigen assay, in addition to samples selected for 249 genotyping by the field diagnostic tests, samples could be selected for *pfhrp2* and *pfhrp3* 250 genotyping based solely on laboratory results. Of all 7,543 DBS screened by the multiplex antigen 251 assay, malaria antigen could not be detected in 5,126 (68.0%) samples. Of the 2,417 DBS positive 252 for any antigens, 2,398 (99.2%) of these were found to have a typical relationship of the pan-253 *Plasmodium* markers with HRP2 (Figure 3). Of the remaining 19 DBS which were all positive for 254 the pan-Plasmodium antigens; 6 had a complete absence of HRP2 antigen, and 13 had an atypical 255 relationship between the assay signal for the pan marker and HRP2. All of these 19 were positive 256 for *P. falciparum* DNA and could thus be utilized for genotyping PCRs. Together with the 16 257 samples chosen initially based on field test results, these 35 samples (16 + 19) were gathered as the 258 final set with suspicion of aberrant HRP2 and/or HRP3 antigen production and warranted 259 genotyping for the *pfhrp2* and *pfhrp3* genes.

260

Table 2 outlines the *pfhrp2* and *pfhrp3* genotyping results for these 35 samples, as well as other information regarding characteristics of the individuals, field test results, and other factors. Most of the samples (31/35, 88.6%) were found to successfully amplify the *pfhrp2* and *pfhrp3* genes for the two exons of each gene. However, one or more of the *pfhrp2* and *pfhrp3* exon targets could not be amplified for 4 (11.4%) DNA samples. To correctly report the presence of a deletion (i.e. lack of

PCR amplification), we chose to include amplification targets for two other single-copy genes (*pfmsp1* and *pfmsp2*) to verify true non-amplification event [31]. For these 4 DNA samples, all were unable to consistently amplify both *pfmsp1* and *pfmsp2* single-copy genes and were excluded in the analysis. For this reason, non-amplification of *pfhrp2* and *pfhrp3* targets due to true deletion events could not be verified, and thus, no deletions in these genes could be confirmed in the remaining 31 samples.

272

273 **DISCUSSION**

274 The samples used in this study were collected during a community-based survey which was 275 conducted in four regions with persistently high malaria burden over the past 10yrs and used to 276 assess the presence and prevalence of *pfhrp2* and *pfhrp3* gene deletions in Tanzania. The findings 277 from field mRDT and microscopy tests as well as the laboratory multiplex antigen test indicate that 278 the vast majority of *P. falciparum* infections in Tanzania produced high levels of HRP2 (and HRP3) 279 antigens which would be recognized by HRP2-based mRDTs. Although mRDTs did not detect some 280 infections from persons confirmed to be P. falciparum positive by PCR, the evidence presented here 281 suggests that these false negative mRDT results were not due to *pfhrp2* and *pfhrp3* gene deletion, 282 and more a factor of low parasite density infections.

283

284 During the survey, extensive efforts were taken to protect the quality of the mRDTs. The 285 experienced study team ensured that mRDTs were stored in appropriate conditions as per the 286 manufacturers' instructions; transported in good conditions (ambient temperature with minimal 287 humidity) and the tests were also performed by experienced technician. To minimize operator 288 errors, the testing process and reading of mRDT results were done in the presence of other members 289 of the team who ensured that any doubtful mRDTs results were correctly read and interpreted. 290 Studies conducted elsewhere reported that the performance of HRP2-based mRDTs depends on the 291 level of parasitaemia [1,8,47], with the lower limit of detection generally around 200 parasites/µL

292 [1]. This community survey included mainly asymptomatic persons, and some had low-level (sub-293 detectable by mRDT) parasitaemia; this could possibly explain some of the discordance between 294 the field mRDT results and the laboratory antigen test. In total 1,998 (27.3% of all) persons were 295 concordant between those two tests, whereas 372 (6.0%) individuals were positive for the mRDT 296 alone and 325 (4.4%) were positive only by the laboratory antigen test. As mRDTs are designed for 297 reliable detection of parasite densities more typical of clinical relevance (200p/uL or greater), their 298 use in the asymptomatic population may miss low-density infections and HRP2 levels [46]. Even in 299 this community setting, it was encouraging to see that mRDTs were able to detect the majority of 300 persons with malaria antigenemia as determined by the laboratory antigen test. Of 2,323 total 301 samples found to be antigen positive, 1,998 (86.0%) came from persons who were mRDT positive. 302 Considering the generally low parasite densities for any *P. falciparum*-infected persons in this 303 survey, concordance was also good for all three tests; microscopy, RDTs, and the laboratory antigen 304 test. Of 1,158 total microscopy positives, 1,063 (91.8%) were also mRDT positive, and 1,050 305 (90.7%) were also positive by the laboratory antigen test. Concordance among multiple malaria 306 indicators provides greater confidence for the true levels of malaria in a populace.

307

308 Of the 35 samples selected for further molecular investigation, which were positive for P. 309 *falciparum* by PCR, the majority (27/35) had relatively low parasite densities ranging from 0 to 310 1,000 parasite/µl. However, eight samples were from persons with higher parasite densities (>1,000 311 asexual parasites/µl), and two of these samples had very high parasite density (88,600 and 104,000 312 parasite/µl). Two of these eight persons gave negative mRDT results which could potentially be 313 explained by the prozone effect where excess of antigen leads to false-negative results [48]. All 314 eight of these higher density infections were found to have detectable HRP2 antigen, though at 315 much lower blood concentrations than typical given those levels of *P. falciparum* parasite densities.

316

The multiplex antigen screening allowed for reconfirmation of HRP2 (and possibly HRP3) antigen profiles for DBS samples. Of all 7,543 samples screened by the multiplex antigen test, few (28, 0.4%) samples had a complete absence of HRP2 or an aberrant relationship between the assay signal for the pan marker and HRP2. This could be due to very low parasite densities or infection with a non-*P. falciparum* infection, but this observation could not be explained by deletions of the *pfhrp2* and *pfhrp3* genes.

323

324 Our report adds to the literature in the same way as studies in Honduras [45] and French Guiana 325 [49] where no deletion of *pfhrp2* gene were reported. However, these findings are in contrast with 326 the results from a recent study which was conducted in Mbeya, Mtwara, and Mwanza regions in 327 Tanzania using samples collected in 2010, one year following the introduction of mRDTs. That 328 study found evidence of sporadic occurrence of *pfhrp2 and pfhrp3* gene deletion in some areas, with 329 1.7% of isolates tested reported to have a deletion of either of the genes [30]. Though recommended 330 molecular tests [31] were used in this study, the overall study was very small with only 176 331 Tanzanian samples tested. Malaria endemicity and year of sampling could potentially explain the 332 different results between the present and the previous surveys, but with the very low estimates for 333 prevalence from the 2010 study, there is a potential that those parasite strains are still present at very 334 low-levels in these regions.

335

A limitation of the current study is that single gene deletions of *pfhrp2* or *pfhrp3* alone could be masked by a parasite producing at least one of these antigens. Deletions (or loss-of-function mutations) in both genes would lead to a complete absence of HRP2/HRP3 antigens in a *P. falciparum* infection. However, if one of these antigens was being produced by the parasite, the algorithm defined here may not identify the blood sample as suspicious if the assay signal for HRP2 remains high. Additionally, the molecular tests performed here were only for complete gene deletions, and any loss-of-function point mutations leading to antigen non-expression would not be

343 captured since the *pfhrp2* or *pfhrp3* specific DNA amplification would still occur using the current 344 protocol. Another limitation from the study is that it does not provide estimates for entire country, 345 since only 4 out of the 26 regions of mainland Tanzania were included in this study. Further studies 346 would need to be conducted on *P. falciparum* isolates collected from other geographical regions of 347 Tanzania (especially in low transmission areas) in order to increase the chances of detecting *pfhrp2* 348 and *pfhrp3* gene deletion in different parts of the country.

349

350 CONCLUSIONS

Though a low number of false negative mRDT results were found in Tanzania, these could not be explained by *pfhrp2* or *pfhrp3* gene deletions. Overall the study results suggest that HRP2-based mRDTs for detection of *P. falciparum* infection and confirmatory diagnosis of malaria in the surveyed area in Tanzania can be used as a reliable tool for malaria case management.

355

356 Funding

The field component of this study was supported by The Global Fund through National Malaria Control Programme of the Tanzanian Ministry of Health. The CDC laboratory work was supported by Malaria Branch and Catherine Bakari's MSc studies was funded by the Developing Excellence in Leadership and Genomics for Malaria Elimination (DELGEME) project with funding from the Developing Excellence in Leadership and Training (DELTAS) Africa Initiative, of the African Academy of Sciences (AAS).

363

364 Acknowledgments

The authors would like to thank the survey teams and study participants for their involvement in the survey in which the tested samples were collected. CB and DSI are supported by DELGEME through the DELTAS Africa Initiative (DELGEME grant 107740/Z/15/Z). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance

369	for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for
370	Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the
371	Wellcome Trust (DELGEME grant 107740/Z/15/Z) and the UK government. The views expressed
372	in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency,
373	Wellcome Trust, or the UK government.
374	
375	
376	Conflict of Interests
377	The authors declare no competing financial interests.
378	
379	Author Contributions
380	Coordination of field surveys: C.I.M., M.G.C., S.R., F.C., F.M., R.M., S.M., A.M., C.K.K., S.G.N.,
381	D.S.I. Conceived and designed experiments: V.U., E.R., D.S.I. Performed the experiments: C.B.,
382	S.J., G.S., C.H., D.P.N., E.R. Analyzed the data: C.B., E.R., D.S.I. Contributed reagents, materials,
383	and analysis tools: V.U., E.R. Manuscript preparation: C.B., V.U., E.R., D.S.I. All authors reviewed
384	and approved the final manuscript.
385	
386	Disclaimer
387	The findings and conclusions presented in this report are those of the authors and do not necessarily
388	reflect the official position of the Centers for Disease Control and Prevention. Ritha Njau is a staff
389	member of the World Health Organization. She alone is responsible for the views expressed in this
390	publication, which do not necessarily represent the decisions, policy or views of the World Health
391	Organization.
392	
393	REFERENCES

1. Moody A. Rapid Diagnostic Tests for Malaria Parasites. **2002**; 15(1):66–78.

- 395 2. WHO. New Perspectives: Malaria Diagnosis: Report of a Joint WHO/USAID Informal
- 396 Consultation. Who [Internet]. **2000**; (October 1999):1–29. Available from:
- 397 http://www.who.int/malaria/publications/atoz/who_cds_rbm_2000_14/en/%0Ahttp://www.w
- 398 ho.int/tdr/publications/documents/malaria-diagnosis.pdf
- 399 3. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. Clin
- 400 Microbiol Infect [Internet]. European Society of Clinical Infectious Diseases; 2013;
- 401 19(5):399–407. Available from: http://dx.doi.org/10.1111/1469-0691.12151
- 402 4. Bell D, Wongsrichanalai C, Barnwell JW et al. Ensuring quality and access for malaria
- 403 diagnosis: How can it be achieved? Nat Rev Microbiol. **2006**; 4(9):682–695.
- 404 5. Masanja MI, McMorrow M, Kahigwa E, Kachur SP, McElroy PD. Health workers' use of
- 405 malaria rapid diagnostic tests (RDTS) to guide clinical decision making in rural dispensaries,
- 406 Tanzania. Am J Trop Med Hyg. **2010**; 83(6):1238–1241.
- 407 6. Rutta ASM, Francis F, Mmbando BP, et al. Using community-owned resource persons to
- 408 provide early diagnosis and treatment and estimate malaria burden at community level in
- 409 north-eastern Tanzania. Malar J. **2012**; 11:1–8.
- 410 7. Thiam S, Thior M, Faye B, et al. Major Reduction in Anti-Malarial Drug Consumption in
- 411 Senegal after Nation-Wide Introduction of Malaria Rapid Diagnostic Tests. PLoS One. 2011;
 412 6(4).
- 413 8. Murray CK, Gasser RA, Magill AJ, Miller RS. Update on rapid diagnostic testing for
 414 malaria. Clin Microbiol Rev. 2008; 21(1):97–110.
- 415 9. WHO. Global Malaria Programme WHO: World Malaria Report 2012. 2012; :V–195.
- 416 10. Rock EP, Marsh K, Taylor DW, et al. Comparative analysis of the Plasmodium falciparum
- 417 histidine-rich proteins HRP-I, HRP-II and HRP-III in malaria parasites of diverse origin.
- 418 Parasitology. **1987**; 95(2):209–227.
- 419 11. Lee N, Baker J, Andrews KT, et al. Effect of sequence variation in Plasmodium falciparum
 420 histidine-rich protein 2 on binding of specific monoclonal antibodies: Implications for rapid

421		diagnostic tests for malaria. J Clin Microbiol. 2006; 44(8):2773–2778.
422	12.	Lee N, Gatton ML, Pelecanos A, et al. Identification of optimal epitopes for Plasmodium
423		falciparum rapid diagnostic tests that target histidine-rich proteins 2 and 3. J Clin Microbiol.
424		2012 ; 50(4):1397–1405.
425	13.	Wellems TE, Howard RJ. Homologous genes encode two distinct histidine-rich proteins in a
426		cloned isolate of Plasmodium falciparum. Proc Natl Acad Sci U S A [Internet]. 1986;
427		83(16):6065–9. Available from:
428		http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=386439&tool=pmcentrez&render
429		type=abstract
430	14.	Kemp DJ, Thompson JK, Walliker D, Corcoran LM. Molecular karyotype of Plasmodium
431		falciparum: conserved linkage groups and expendable histidine-rich protein genes. Proc Natl
432		Acad Sci. 2006; 84(21):7672–7676.
433	15.	Gamboa D, Ho MF, Bendezu J, et al. A large proportion of P. falciparum isolates in the
434		Amazon region of Peru lack pfhrp2 and pfhrp3: Implications for malaria rapid diagnostic
435		tests. Bjorkman A, editor. PLoS One [Internet]. Public Library of Science; 2010 [cited 2018
436		Apr 6]; 5(1):e8091. Available from: http://dx.plos.org/10.1371/journal.pone.0008091
437	16.	Maltha J, Gamboa D, Bendezu J, et al. Rapid Diagnostic Tests for Malaria Diagnosis in the
438		Peruvian Amazon: Impact of pfhrp2 Gene Deletions and Cross-Reactions. PLoS One. 2012;
439		7(8):1–7.
440	17.	Koita OA, Doumbo OK, Ouattara A, et al. False-negative rapid diagnostic tests for malaria
441		and deletion of the histidine-rich repeat region of the hrp2 gene. Am J Trop Med Hyg. 2012;
442		86(2):194–198.
443	18.	Berhane A, Russom M, Bahta I, Hagos F, Ghirmai M, Uqubay S. Rapid diagnostic tests
444		failing to detect Plasmodium falciparum infections in Eritrea: An investigation of reported
445		false negative RDT results. Malar J. BioMed Central; 2017; 16(1):1-6.
446	19.	Parr JB, Verity R, Doctor SM, et al. Pfhrp2 -Deleted Plasmodium falciparum Parasites in the

447	Democratic Republic of the Congo: A National Cross-sectional Survey. J Infect Dis. 2017;

- 448 216(1):36–44.
- 449 20. Viana GMR, Okoth SA, Silva-Flannery L, et al. Histidine-rich protein 2 (pfhrp2) and pfhrp3
- 450 gene deletions in Plasmodium falciparum isolates from select sites in Brazil and Bolivia.
- 451 PLoS One. **2017**; 12(3):1–13.
- 452 21. Beshir KB, Sepúlveda N, Bharmal J, et al. Plasmodium falciparum parasites with histidine-
- 453 rich protein 2 (pfhrp2) and pfhrp3 gene deletions in two endemic regions of Kenya. Sci Rep.

454 2017; 7(1):1–10.

- 455 22. Bharti PK, Chandel HS, Ahmad A, Krishna S, Udhayakumar V, Singh N. Prevalence of
- 456 pfhrp2 and/or pfhrp3 gene deletion in plasmodium falciparum population in eight highly
- 457 endemic states in India. PLoS One. **2016**; 11(8):1–16.
- 458 23. Baker J, McCarthy J, Gatton M, et al. Genetic Diversity of *Plasmodium falciparum*
- 459 Histidine Rich Protein 2 (PfHRP2) and Its Effect on the Performance of PfHRP2 Based
- 460 Rapid Diagnostic Tests. J Infect Dis [Internet]. **2005**; 192(5):870–877. Available from:

461 https://academic.oup.com/jid/article-lookup/doi/10.1086/432010

- 462 24. Wurtz N, Fall B, Bui K, et al. Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum
- 463 isolates from Dakar, Senegal: Impact on rapid malaria diagnostic tests. Malar J. 2013;
- 464 12(1):1–8.
- 465 25. Atroosh WM, Al-Mekhlafi HM, Al-Jasari A, et al. Genetic variation of pfhrp2 in Plasmodium

466 falciparum isolates from Yemen and the performance of HRP2-based malaria rapid

- 467 diagnostic test. Parasites and Vectors [Internet]. Parasites & Vectors; **2015**; 8(1):1–8.
- 468 Available from: http://dx.doi.org/10.1186/s13071-015-1008-x
- 469 26. Li P, Xing H, Zhao Z, et al. Genetic diversity of Plasmodium falciparum histidine-rich
- 470 protein 2 in the China-Myanmar border area. Acta Trop. **2015**; 152:26–31.

471 27. Kozycki CT, Umulisa N, Rulisa S, et al. False-negative malaria rapid diagnostic tests in

472 Rwanda: impact of Plasmodium falciparum isolates lacking hrp2 and declining malaria

- 473 transmission. Malar J. **2017**; 16(1):1–11.
- 474 28. Gendrot M, Fawaz R, Dormoi J, Madamet M, Pradines B. Genetic diversity and deletion of
- 475 Plasmodium falciparum histidine-rich protein 2 and 3: a threat to diagnosis of P. falciparum
- 476 malaria. Clin Microbiol Infect [Internet]. Elsevier Ltd; **2018**; :2–7. Available from:
- 477 https://doi.org/10.1016/j.cmi.2018.09.009
- 478 29. Ramutton. T, Hendriksen. IC, Mwanga-Amumpaire. J, et al. Sequence variation does not
- 479 confound the measurement of plasma PfHRP2 concentration in African children presenting
- 480 with severe malaria. Malar J [Internet]. **2012**; 11:276. Available from:
- 481 http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52169263
- 482 %0Ahttp://dx.doi.org/10.1186/1475-2875-11-
- 483 276%0Ahttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=14752875&id=doi:10.1186%2F
- 484 1475-2875-11-276&atitle=Sequence+variation+does+no
- 485 30. Thomson R, Beshir KB, Cunningham J, et al. Title:pfhrp2 and pfhrp3 gene deletions that
- 486 affect malaria rapid diagnostic tests for for Plasmodium falciparum: analysis of archived

487 blood samples from three African countries. **2019**; .

- 488 31. Cheng Q, Gatton ML, Barnwell J, et al. Plasmodium falciparum parasites lacking histidine-
- 489 rich protein 2 and 3: a review and recommendations for accurate reporting. Malar J
- 490 [Internet]. **2014**; 13(1):283. Available from:
- 491 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4115471&tool=pmcentrez&rende
 492 rtype=abstract
- 493 32. TACAIDS. Tanzania 2007-08 HIV/AIDS and Malaria Indicator Survey Key Findings.
- 494 Tanzania 2007-08 HIV/AIDS Malar Indic Surv Key Find. 2008; (HIV Prevalence):16.
- 495 33. TACAIDS. Tanzania- 2011-12 HIV/AIDS and Malaria Indicator Survey 2011-12: Key
- 496 Findings. Tanzania Comm AIDS (ZAC), Zanzibar AIDS Comm (NBS), Natl Bur Stat
- 497 (OCGS), Off Chief Gov Stat ICF Int. **2013**; :16.
- 498 34. TDHS-MIS. Tanzania Demographic and Health Survey and Malaria Indicator Survey

- 499 (TDHS-MIS) 2015-16. Dar es Salaam, Tanzania, Rockville, Maryl USA [Internet]. 2016;
- 500 :172–173. Available from: https://www.dhsprogram.com/pubs/pdf/FR321/FR321.pdf
- 501 35. THIS. Summary Sheet: Preliminary Findings 2016-2017. 2017; (December 2017):2016–
- 502 2017. Available from: http://www.nbs.go.tz/nbs/takwimu/this2016-
- 503 17/Tanzania_SummarySheet_English.pdf
- 504 36. Chacky F, Runge M, Rumisha SF, et al. Nationwide school malaria parasitaemia survey in
- 505 public primary schools, the United Republic of Tanzania. Malar J [Internet]. BioMed Central;
- 506 **2018**; 17(1):1–16. Available from: https://doi.org/10.1186/s12936-018-2601-1
- 507 37. Chiduo MG, Mandara CI, Rumisha SF, et al. Assessing the intrinsic and extrinsic drivers and
- 508 targeting the observed resilience of malaria in northwestern and southern Tanzania: A
- 509 protocol for a cross-sectional exploratory study. **2020**; :1–46.
- 510 38. MoH. National Guidelines for Diagnosis and Treatment of Malaria. Dar es Salam, Tanzania:
- 511 Ministry of Health and Social Welfare, United Republic of Tanzania; **2006**; (January).
- 512 39. Plucinski MM, Cruz KR, Ljolje D, et al. Screening for Pfhrp2/3 -Deleted Plasmodium
- 513 falciparum, Non- falciparum, and Low-Density Malaria Infections by a Multiplex Antigen
- 514 Assay. J Infect Dis. **2018**; 219(3):437–447.
- 515 40. Lucchi NW, Karell MA, Journel I, et al. PET-PCR method for the molecular detection of
- 516 malaria parasites in a national malaria surveillance study in Haiti, 2011. Malar J. 2014;
- 517 13:462.
- 518 41. Akerele D, Ljolje D, Talundzic E, Venkatachalam, Udhayakumar Lucchi WN. Molecular
- 519 diagnosis of malaria by photo-induced electron transfer fluorogenic primers (PET-PCR). Am
- 520 J Trop Med Hyg [Internet]. **2017**; Conference:258. Available from:
- 521 http://www.ajtmh.org/content/87/5_Suppl_1/226.full.pdf+html%5Cnhttp://ovidsp.ovid.com/o
- 522 vidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=71041482%5Cn
- 523 http://eleanor.lib.gla.ac.uk:4550/resserv?sid=OVID:embase&id=pmid:&id=doi:&issn=0002-
- 524 9637&isbn=&volum

525	42.	Kudyba HM, Louzada J, Ljolje D, et al. Field evaluation of malaria malachite green loop-
526		mediated isothermal amplification in health posts in Roraima state, Brazil. Malar J [Internet].
527		BioMed Central; 2019; 18(1):1–7. Available from: https://doi.org/10.1186/s12936-019-2722-
528		1
529	43.	Sitali L, Miller JM, Mwenda MC, et al. Distribution of Plasmodium species and assessment
530		of performance of diagnostic tools used during a malaria survey in Southern and Western
531		Provinces of Zambia. Malar J [Internet]. BioMed Central; 2019 ; 18(1):1–9. Available from:
532		https://doi.org/10.1186/s12936-019-2766-2
533	44.	Akinyi S, Magill AJ, Torres K, et al. Multiple genetic origins of histidine-rich protein 2 gene
534		deletion in Plasmodium falciparum parasites from Peru. Sci Rep. 2013; 3(1):1–8.
535	45.	Abdallah JF, Okoth SA, Fontecha GA, et al. Prevalence of pfhrp2 and pfhrp3 gene deletions
536		in Puerto Lempira, Honduras. Malar J. 2015; 14(1):1–9.
537	46.	Plucinski M, Dimbu R, Candrinho B, et al. Malaria surveys using rapid diagnostic tests and
538		validation of results using post hoc quantification of Plasmodium falciparum histidine-rich
539		protein 2. Malar J. BioMed Central; 2017 ; 16(1):1–7.
540	47.	Benton CB, Nazha A, Pemmaraju N, et al. HHS Public Access. 2016; 95(2):222–242.
541	48.	Luchivez J, Baker J, Alcantara S, et al. Laboratory demonstration of a prozone effect HRP2
542		detecting malaria diagnostic tests: implications for clinical management. Malar J [Internet].
543		2011 ; 10:1–7. Available from: http://dx.doi.org/10.1186/1475-2875-10-286
544	49.	Trouvay M, Palazon G, Berger F, et al. High Performance of Histidine-Rich Protein 2 Based
545		Rapid Diagnostic Tests in French Guiana are Explained by the Absence of pfhrp2 Gene
546		Deletion in P. falciparum. PLoS One. 2013; 8(9):1–7.
547		
548		
549		

550 Tables

551 Table 1: Baseline characteristics of individuals sampled in each of the four regions

	Mtwara Geita		Kigoma	Ruvuma	Total	
Number of HHs registered	1,306	1,209	1,490	2,202	6,207	
Number of HHs sampled n (%)	684 (27.1)	533 (21.2)	587 (23.3)	716 (28.4)	2520 (40.5)	
Number of individuals in HHs	4,723	6,994	7,945	8,699	28,361	
Number of individual sampled; n (%)	1,548 (21.2)	2,053 (28.1)	1,979 (27.1)	1,733 (23.7)	7,313 (25.8)	
Age in years; mean (SD)	25.3 (22.1)	18.2 (18.2)	22.4 (22.1)	24.3 (21.3)	22.3 (21.0)	
Sex = Male; n (%)	702 (22.1)	878 (27.7)	850 (26.8)	742 (23.4)	3,172 (43.4)	
Microscopy positive; n (%)*	209 (13.9)	361 (24.0)	558 (37.1)	378 (25.1)	1,506 (20.6)	
mRDTs positive n(%)*	553 (22.7)	556 (22.8)	737 (30.2)	591 (24.3)	2,437 (33.3)	
Fever [†] - Yes; n (%)*	245 (16.2)	261 (17.2)	736 (48.5)	275 (18.1)	1,517 (20.5)	
GMPD of positives; p/ul, (95% CI)	385 (299-495)	774 (643-931)	583 (482-706)	527 (435-638)	575 (516-637)	

HH: Household SD: standard deviation

N: number of individuals

GMPD: geometric mean parasite density

CI: Confidence interval

*N=7,313

[†]Fever within the past two weeks

552

553

554

555

556

557

559 Table 2. Summary of *pfhrp2* and *pfhrp3* genotyping results for the samples selected based on

560 field mRDT and microscopy results, laboratory antigen assay, or both.

561

Sample #	Selected on:	District	Age	RDT Result	Microscopy Parasite Density (p/uL)	PET Pf Ct	pAldo (ng/mL)	pLDH (ng/mL)	HRP2 (ng/mL)	pfhrp2 exons 1/2	pfhrp3 exons 1/2	pf msp1*	pf msp2*
1	aldo	Chiulu	6	+	256	35.1	43.9	3.7	1.0	+/+	+/+		
2	aldo	Chiulu	6	-	0	35.6	40.6	2.7	0.0	+/+	+/+		
3	rdt	Chiulu	33	-	80	38.3	0.0	0.0	0.0	+/+	+/+		
4	rdt	Herembe	3	-	520	31.8	28.4	2.8	1.0	+/+	+/+		
5	ldh	Kasenga	54	+	1717	33.8	26.0	6.0	1.0	+/+	+/+		
6	ldh	Kasenga	10	+	1840	33.5	30.6	10.6	1.9	+/+	+/+		
7	aldo	Kasenga	6	+	591	35	62.3	6.0	1.7	+/+	+/+		
8	aldo	Kasenga	4	+	440	33.9	46.5	4.1	1.4	+/+	+/+		
9	rdt	Kasenga	4	-	32	35	0.0	0.0	0.0	+/+	+/+		
10	rdt	Kasenga	13	-	96	33.3	0.0	0.0	0.8	+/+	+/+		
11	rdt	Kasenga	0	-	221	33.7	0.0	0.0	0.0	+/+	+/+		
12	ldh aldo	Katale	2	+	480	31.8	360.9	114.6	21.2	+/+	+/+		
13	ldh aldo	Katale	4	+	2628	28.7	797.1	214.5	42.4	+/+	+/+		
14	ldh aldo	Katale	10	-	0	35.3	76.4	8.9	0.2	+/+	+/+		
15	ldh aldo rdt	Katale	9	-	2000	28.2	210.8	62.4	5.0	+/+	+/+		
16	aldo rdt	Katale	4	-	280	31	44.1	0.0	0.0	+/+	-/-	-/-	+/-
17	ldh aldo	Kigege	2	+	48	32.4	190.5	80.3	12.4	+/+	+/+		
18	rdt	Kigege	38	-	16	38.9	0.0	0.0	0.0	+/+	-/+	-/+	-/-
19	rdt	Kigege	8	-	520	34.8	0.0	0.0	0.0	+/+	+/+		
20	ldh	Kitunguli	6	+	0	31.5	42.9	39.2	1.5	+/+	+/+		
21	rdt	Mkowela	43	-	440	37.3	0.0	0.0	0.0	+/+	+/-	+/-	-/+
22	aldo	Mkowela	2	+	0	35.3	51.0	5.4	1.3	+/+	+/+		
23	ldh aldo	Mkowela	11	-	0	35.8	46.3	5.6	0.0	+/+	+/+		
24	aldo	Mkunwa	3	+	48	36	33.0	5.9	0.1	+/+	+/+		
25	rdt	Mtawarawa	14	-	176	33.2	0.0	0.0	0.0	+/+	+/+		
26	rdt	Mtawarawa	22	-	96	34.9	0.0	0.0	0.1	+/+	+/+		
27	ldh	Mwamila	2	+	11480	27.6	338.3	159.4	35.5	+/+	+/+		
28	ldh aldo rdt	Nyangalamila	8	-	288	34	54.7	11.0	0.0	+/+	+/+		
29	ldh aldo	Nyankoronko	7	+	104000	25.7	760.1	242.9	37.5	+/+	+/+		
30	ldh aldo	Nyankoronko	2	+	160	33.8	98.8	18.3	2.1	+/+	+/+		
31	ldh aldo	Nyankoronko	4	+	28800	29.8	76.2	19.1	0.9	+/+	+/+		
32	ldh	Nyankoronko	6	+	440	36.5	24.2	7.9	1.4	+/-	+/+	+/-	+/-
33	aldo rdt	Nyankoronko	43	-	48	37	31.3	0.0	0.0	+/+	+/+		
34	rdt	Nyankoronko	10	-	760	31.3	0.0	0.0	0.8	+/+	+/+		
35	ldh rdt	Nyankoronko	9	-	88600	25.5	187.5	85.1	16.6	+/+	+/+		

*, Antigen listed indicates aberrant relationship between HRP2 and that antigen's assay signal; mRDT indicates microscopy/mRDT discordance

[†], Genotyping for pfmsp1 and pfmsp2 not performed if sample showed amplification for all pfhrp2 and pfhrp3 targets

562

564 Figures



568 Figure 1: Map showing the study sites in the four regions of Tanzania





574 Figure 2. Flowchart for selection of samples requiring genotyping for *pfhrp2* and *pfhrp3*.

575 Samples were selected based on initial field microscopy and mRDT results (shown on left), or 576 multiplex laboratory antigen detection (shown on right), for final determination of samples 577 requiring genotyping to detect potential deletion of pfhrp2/3 genes.



587

588 Figure 3. Scatterplots of pan-Plasmodium LDH or aldolase assay signal in comparison with 589 **HRP2** assay signal. Plots designate samples that were selected for further genotyping investigation 590 as based on an atypical relationship to the pan-Plasmodium LDH (A) or aldolase (B) antigens. 591 Hashed lines in each plot show MFI-bg assay signal threshold which would indicate a positive 592 assay signal for each antigen. Black circles indicate samples selected based on field RDT result as 593 well as laboratory antigen assay that were P. falciparum DNA positive. Red circles indicate samples 594 selected solely based on laboratory antigen assay that were *P. falciparum* DNA positive. Squares 595 indicate samples selected solely based on laboratory antigen assay that were P. falciparum DNA 596 negative.